You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三葉草生物(02197.HK)二價新冠候選疫苗顯示對奧密克戎變異株有中和作用
阿思達克 05-05 22:09
三葉草生物-B(02197.HK)公佈,核心產品二價新冠候選疫苗臨牀前研究中發現,其作爲基礎疫苗和加強針接種,誘導了對包括奧密克戎在內的所有值得關注的變異株的廣譜中和作用。 此項臨牀前研究中,二價新冠候選疫苗由來自原始毒株的三聚體刺突蛋白(SCB-2019)和來自奧密克戎變異株的三聚體刺突蛋白(SCB-2022B)組成。在接受基礎免疫和加強針接種(之前接種了兩劑原型疫苗)的小鼠中,二價新冠候選疫苗顯示對包括奧密克戎變異株在內的所有值得關注的變異株具有有效的中和作用。重要的是,與單價奧密克戎變異株疫苗(SCB-2022B)單獨比較,二價新冠疫苗針對試驗中測試的絕大多數變異株顯示了更高的中和抗體水平,針對奧密克戎顯示出相似的中和抗體水平。 公司計劃將此二價新冠候選疫苗開發推進到臨牀開發階段,還預計在今年第二季度啓動一項1期試驗來評估SCB-2020S(一種野生型毒株和貝塔變異株嵌合S-三聚體候選疫苗)以展示應用Trimer-Tag(蛋白質三聚體化)平臺技術研發應對未來新冠病毒變異株廣譜疫苗的概念驗證。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account